Zobrazeno 1 - 10
of 114
pro vyhledávání: '"Peter Mullen"'
Autor:
Dillum Patel, Alison L. Dickson, Greice M. Zickuhr, In Hwa Um, Oliver J. Read, Clarissa M. Czekster, Peter Mullen, David J. Harrison, Jennifer Bré
Publikováno v:
Translational Oncology, Vol 50, Iss , Pp 102114- (2024)
The combination of gemcitabine with platinum agents is a widely used chemotherapy regimen for a number of tumour types. Gemcitabine plus cisplatin remains the current therapeutic choice for biliary tract cancer. Gemcitabine is associated with multipl
Externí odkaz:
https://doaj.org/article/c3c62a6cd41e4e5e96928c106ddb18b1
Autor:
Kate M. Moore, Vera Cerqueira, Kenneth G. MacLeod, Peter Mullen, Richard L. Hayward, Simon Green, David J. Harrison, David A. Cameron, Simon P. Langdon
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 3, Iss 1, Pp 97-116 (2022)
Aim: A model of progressively endocrine-resistant breast cancer was investigated to identify changes that can occur in signaling pathways after endocrine manipulation. Methods: The MCF7 breast cancer model is sensitive to estrogens and anti-estrog
Externí odkaz:
https://doaj.org/article/1befcc865c8d466aa9837be2e933674b
Autor:
Michael Taynnan Barros, Harun Siljak, Peter Mullen, Constantinos Papadias, Jari Hyttinen, Nicola Marchetti
Publikováno v:
Molecules, Vol 27, Iss 19, p 6256 (2022)
The classification of biological neuron types and networks poses challenges to the full understanding of the human brain’s organisation and functioning. In this paper, we develop a novel objective classification model of biological neuronal morphol
Externí odkaz:
https://doaj.org/article/ec9636e4c4494796908977ce0f4dffa4
Autor:
Alexander L. R. Lubbock, Grant D. Stewart, Fiach C. O’Mahony, Alexander Laird, Peter Mullen, Marie O’Donnell, Thomas Powles, David J. Harrison, Ian M. Overton
Publikováno v:
BMC Medicine, Vol 15, Iss 1, Pp 1-12 (2017)
Abstract Background Metastatic clear cell renal cell cancer (mccRCC) portends a poor prognosis and urgently requires better clinical tools for prognostication as well as for prediction of response to treatment. Considerable investment in molecular ri
Externí odkaz:
https://doaj.org/article/aa90bc574f0f41a1b1be9cae25200d23
Autor:
Arkadiusz Welman, Duncan Sproul, Peter Mullen, Morwenna Muir, Andrew R Kinnaird, David J Harrison, Dana Faratian, Valerie G Brunton, Margaret C Frame
Publikováno v:
PLoS ONE, Vol 7, Iss 4, p e34182 (2012)
Overexpression of matriptase has been reported in a variety of human cancers and is sufficient to trigger tumor formation in mice, but the importance of matriptase in breast cancer remains unclear. We analysed matriptase expression in 16 human breast
Externí odkaz:
https://doaj.org/article/f68ec75a6d1b45c7a524d4794a4d5dae
Autor:
Dana Faratian, Andrew H Sims, Peter Mullen, Charlene Kay, Inhwa Um, Simon P Langdon, David J Harrison
Publikováno v:
PLoS ONE, Vol 6, Iss 8, p e23772 (2011)
Resistance to trastuzumab is a clinical problem, partly due to overriding activation of MAPK/PI3K signalling. Sprouty-family proteins are negative regulators of MAPK/PI3K signalling, but their role in HER2-therapy resistance is unknown.Associations b
Externí odkaz:
https://doaj.org/article/64bdbf45d000409b9204668aede19b7b
Autor:
Jennifer Bré, Alison L. Dickson, Oliver J. Read, Ying Zhang, Fiona G. McKissock, Peter Mullen, Peijun Tang, Greice M. Zickuhr, Clarissa M. Czekster, David J. Harrison
Publikováno v:
Cancer Chemotherapy and Pharmacology. 91:401-412
Introduction Fluoropyrimidines, principally 5-fluorouracil (5-FU), remain a key component of chemotherapy regimens for multiple cancer types, in particular colorectal and other gastrointestinal malignancies. To overcome key limitations and pharmacolo
Autor:
Thomas Powles, David J. Harrison, Ian M. Overton, Michael Aitchison, Axel Bex, Daniel Berney, Antony C.P. Riddick, S. Alan McNeill, Peter Mullen, Marie O'Donnell, Jyoti Nanda, Alan Mackay, Alexander L.R. Lubbock, Lel Eory, Alexander Laird, Fiach C. O'Mahony, Grant D. Stewart
Purpose: The aim of this study was to investigate the effect of VEGF-targeted therapy (sunitinib) on molecular intratumoral heterogeneity (ITH) in metastatic clear cell renal cancer (mccRCC).Experimental Design: Multiple tumor samples (n = 187 sample
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::738a2f7a83396a6b73601baba6b814bd
https://doi.org/10.1158/1078-0432.c.6523416
https://doi.org/10.1158/1078-0432.c.6523416
Autor:
Simon P. Langdon, David J. Harrison, Max Hasmann, Charlene Kay, Inhwa Um, Peter Mullen, Michael Dodds, Morwenna Muir, Andrew H. Sims, Yoko Nagumo, Annelien J.M. Zweemer, Dana Faratian
Purpose: The aim of this study was to investigate the antitumor effects of HER2-directed combination therapy in ovarian cancer xenograft models to evaluate their potential. The combinations of trastuzumab and pertuzumab, and trastuzumab and aromatase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::185653759923b582f1d77952ff490cf1
https://doi.org/10.1158/1078-0432.c.6518218.v1
https://doi.org/10.1158/1078-0432.c.6518218.v1
Autor:
Thomas Powles, David J. Harrison, Ian M. Overton, Michael Aitchison, Axel Bex, Daniel Berney, Antony C.P. Riddick, S. Alan McNeill, Peter Mullen, Marie O'Donnell, Jyoti Nanda, Alan Mackay, Alexander L.R. Lubbock, Lel Eory, Alexander Laird, Fiach C. O'Mahony, Grant D. Stewart
Supplementary Figures 1-2, Supplementary Tables 1-2. Fig. S1. Histogram showing lack of correlation between differential protein and RNA expression levels between sunitinib naive and treated patient samples; Figure S2: Dendrograms illustrating superv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::129c6bfacb49741bef08bee8ccb39e15
https://doi.org/10.1158/1078-0432.22456785
https://doi.org/10.1158/1078-0432.22456785